Jessica Mason
Nurse Practitioner · Bedford, TXNPI 1790940807
Payments from drug & device makers
Across 1,303 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Livanova USA, Inc.$2K
- Biogen$1K
- Teva Pharmaceuticals USA, Inc.$1K
- EMD Serono, Inc.$1K
- Inspire Medical Systems, Inc.$961
- plus $16K from 54 others
What the payments were for
- Travel & lodging$1,4065%
- Food & beverage$23,62792%
- Education$5282%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,561 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 19 | $153,931 |
| CopaxoneGlatiramer Acetate | 12 | $70,957 |
| Emgality PenGalcanezumab-Gnlm | 54 | $42,780 |
| Aimovig AutoinjectorErenumab-Aooe | 53 | $38,743 |
| Nurtec OdtRimegepant Sulfate | 32 | $34,797 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 34 | $31,941 |
| KeppraLevetiracetam | 12 | $22,612 |
| Memantine Hcl | 599 | $22,332 |
| Trokendi XrTopiramate | 12 | $14,808 |
| NeuproRotigotine | 13 | $13,976 |
| RytaryCarbidopa/Levodopa | 13 | $10,974 |
| LamictalLamotrigine | 12 | $10,596 |
| Gabapentin | 326 | $8,813 |
| Rivastigmine | 22 | $7,607 |
| Dalfampridine ErDalfampridine | 13 | $7,565 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $592 | $153,93119 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $1,205 | $70,95712 claims |
| PfizerNurtec Odt | $727 | $34,79732 claims |
| Supernus Pharmaceuticals, Inc.Trokendi Xr | $190 | $14,80812 claims |
| UCB, Inc.Neupro | $872 | $13,97613 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $48 | $11,97325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in Bedford
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Roger ChapmanTyler$211K
- Kelly BrassilHouston$194K
- Corrie BerkSan Antonio$155K
- Samantha OnealDallas$133K
- Monica WhiteLongview$118K
- Onna FeuchterSouthlake$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.